Sessioni Poster


Antineoplastic drugs

Thursday, October 26th / 19.00-21.00
22OVER-EXPRESSION OF MIR-574-5P INCREASES TUMOR GROWTH IN XENOGRAFTS OF HUMAN LUNG CANCER CELLS VIA PROSTAGLANDIN E2
Bruno A., Saul MJ., Baumann I., Contursi A., Dovizio M., Donnini S., Tacconelli S., Raouf J., Idborg H., Stein S., Korotkova M., Savai R., Salvatore T., Terzuoli E., Jakobsson PJ., Suess B., Steinhilber D., Patrignani P.
35Effects of NO and H2S releasing doxorubicin on a xenograft model of chemoresistant prostate cancer
Cinci L., Bigagli E., De angioletti M., Chegaev K., Riganti C., D'ambrosio M., Saponara S., Luceri C.
626-(METHYLSULFINYL)HEXYLISOTHIOCYANATE AS POTENTIAL CHEMOPREVENTIVE AGENT: MOLECULAR AND CELLULAR PROFILE IN LEUKEMIA CELL LINES
Lenzi M., Cocchi V., Hrelia P.
94TRANSIENT RECEPTOR POTENTIAL VANNILOID TYPE 4 CHANNEL (TRPV4) IS A KEY REGULATOR OF COLORECTAL CANCER DEVELOPMENT
Romano BR., Petti LP., Piontini AP., Correale CC., Izzo AA., Danese SD., Vetrano SV.
122ACETYL DEACYLASADISULFIDE, A NATURAL H2S DONOR MOLECULE, INHIBITS METASTATIC MELANOMA.
Armogida C., Panza E., De cicco P., Ercolano G., Taglialatela-scafati O., Cirino G., Ianaro A.
134Curcumin Potentiates Antitumor Activity of Paclitaxel in Rat Glioma C6 Cells
Bashllari R., Fratantonio D., Molonia MS., Muscarà C., Cristani M., Saija A., Cimino F., Speciale A.
141TARGETING THE CANCER RESISTOME TO RESTORE TUMOUR SENSITIVITY THROUGH NOVEL, EXISTING AND FAILED DRUGS
Angelini S., Bergamo A., Morbidelli L., Pacor S., Terzuoli E., Sava G.
144Melanocortin receptor-4 as a novel therapeutic target in glioblastoma
Vaglini F., Pardini C., Di Desidero T., Orlandi P., Pasqualetti F., Ottani A., Giuliani D., Guarini S., Bocci G.
181A NEW SYNTHETIC ISOTHIOCYANATE DERIVATIVE (MG28) AS AN IMMUNOGENIC CELL DEATH INDUCER: IN VITRO CHARACTERIZATION OF ITS PHARMACO-TOXICOLOGICAL PROFILE.
Catanzaro E.., Calcabrini C.., Milelli A.., Sestili P.., Agostinis P.., Greco G.., Turrini E.., Hrelia P.., Fimognari C..
188Tumor stemness and cancer drug-resistance: role of aldehyde dehydrogenase 1A1
Ciccone V., Terzuoli E., Donnini S., Morbidelli L., Ziche M.
195ROLE OF MITOCHONDRIA IN CISPLATIN-RESISTANCE PHENOMENA
Cocetta V.., Catanzaro D.., Vianello C.., Ragazzi E.., Montopoli M..
201GROWTH HORMONE SECRETAGOGUES PREVENT CISPLATIN-INDUCED MUSCLE WASTING: CHARACTERIZATION OF MULTIPLE MECHANISMS INVOLVING SARCOPLASMIC RETICULUM AND MITOCHONDRIA
Conte E., Pesce V., Camerino GM., Mele A., Sirago G., De bellis M., Pierno S., Rana F., Fonzino A., Rizzi L., Fehrentz J-., Martinez J., Torsello A., Conte D., Cantatore P., Liantonio A.
205PHARMACOLOGICAL CHARACTERIZATION OF NEW ANTAGONIST OF THE EPH RECEPTORS ENDOWED WITH ANTI-ANGIOGENIC ACTIVITY
Corrado M., Giorgio C., Incerti M., Russo S., Ballabeni V., Barocelli E., Lodola A., Tognolini M.
206LIPID CONTENT OF HUMAN TUMOR EXOSOMES MAY EXPLAIN THEIR RESISTANCE IN BIOLOGICAL FLUIDS
Accattatis F.., Ferro S.., De metrio S.., Granata A.., Corsini A.., Huber V.., Arnaboldi L..
230Inhibition of SIRT1 Deacetylase Uncouples Anti-Inflammatory and Chemo-Preventive Actions of NSAIDs
Dell'omo G., Vantaggiato C., Parravicini C., Borroni AP., Rizzi N., Bassi FD., Pruneri G., Conti P., Eberini I., Maggi A., Ciana P.
233Metronomic vinorelbine is active on EGFR-wt and EGFRL858R/T790M Non Small Cell Lung Cancer cells, alone and in combination with EGFR tyrosine kinase inhibitors
Salvia C.G. Orlandi P. Di Desidero T. Muscatello B., Francia G. Bocci G.
234Colon cancer therapy beyond tumor progression: evaluation of the effects of switched schedules and related pharmacodynamic biomarkers.
Di Desidero T., Orlandi P., Fioravanti A., Cremolini C., Antoniotti C., Loupakis F., Falcone A., Bocci G.
255A multiple approach allowed unveiling the mechanism of action of the anti-cancer natural compound oridonin
Vasaturo M., Fiengo L., Cotugno R., Belisario A., De Tommasi N., Filippelli A., Dal Piaz F.
257RIMONABANT KILLS COLON CANCER STEM CELLS WITHOUT INDUCING TOXICITY IN NORMAL COLON ORGANOIDS.
Fiore D., Ramesh P., Proto MC., Piscopo C., Bifulco M., Medema JP., Gazzerro P.
262IN VITRO ASSESSMENT OF CABAZITAXEL ACTIVITY IN ADRENOCORTICAL CARCINOMA CELLS
Fragni M., Palma lopez LP., Rossini E., Galli D., Tiberio GA., Berruti A., Memo M., Sigala S.
275VANADIUM COMPOUNDS INHIBIT CELL PROLIFERATION VIA MAPK AND CELL CYCLE ARREST
Gallicchio M., Barge A., Deagostino A., Ghibaudi E., Laurenti E., Marabello D., Cadamuro S., Diana E., Boscaro V.
279Surfaced-enhanced Raman spectroscopy (SERS) as an innovative pharmacological tool to quantify thiopurine metabolites in immortalized human hepatocytes (IHH).
Genova E., Pelin M., Fornasaro S., Bonifacio A., Decorti G., Stocco G.
284TARGETING S100B-P53WT PROTEIN-PROTEIN INTERACTION WITH PENTAMIDINE: A NOVEL APPROACH TO CONTRAST CHRONIC INFLAMMATION-INDUCED COLON CANCER DRIFT
Gigli S., Seguella L., Pesce M., Steardo L., Sarnelli G., Esposito G.
339Subcutaneous slow-release metformin formulation grants high tissue drug levels and induce antitumoral effects. An in vivo feasibility pilot study.
Mattioli F., Marini V., Fucile C., Solari A., Daga A., Pattarozzi A., Baldassarri S., Zuccari G., Barbieri F., Caviglioli G., Florio T.
349Curcumin Ameliorates the In Vitro Efficacy of Carfilzomib in Human Multiple Myeloma U266 Cells Targeting p53 and NF-_B Pathways
Molonia MS., Speciale A., Alllegra A., Guglielmo L., Musolino C., Saija A., Cimino F.
351GLUCOSE-6-PHOSPHATE DEHYDROGENASE AS PHARMACOLOGICAL TARGET TO OVERCOME CISPLATIN RESISTANCE
Catanzaro D., Gaude E., Orso G., Guzzo G., Rasola A., Ragazzi E., Caparrotta L., Frezza C., Montopoli M.
361SELECTION AND CHARACTERIZATION OF A HUMAN OVARIAN CANCER CELL LINE RESISTANT TO AURANOFIN
Nobili S., Landini I., Lapucci A., Pratesi A., Massai L., Napoli C., Perrone G., Pinzani P., Messori L., Mini E.
362MDA-9/SYNTENIN AS A POTENTIAL DRUG TARGET IN HEPATOCELLULAR CARCINOMA
Notarbartolo M., Labbozzetta M., D'alessandro N., Poma P.
367TRPM8 and experimental colorectal cancer: pharmacological evidence
Pagano E., Parisi OA., D'armineto M., Iannotti F., Aprea G., Pignatiello S., Izzo AA., Borrelli F.
372Tryptophan 2,3-dioxygenase inhibition: a possible target in cancer immunotherapy
Parenti A., Cardellicchio M., Conciarelli G., Smedile T., Di gennaro P., Gerlini G.
406In vitro identification of molecular determinants that may enhance drug cytotoxicity in the testicular tumor germ cell line NTERA-2.
Rossini E.., Fragni M.., Vezzoli S.., Berruti A.., Memo M.., Sigala S..